Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases

Clinical Trial ID: NCT02831348

Description

This is a pilot cross-sectional study of measured transcutaneous CO-oximetry in children with inflammatory and non-inflammatory conditions.

Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited. Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire forms to characterize their health, current symptoms, medications, and common exposures. Transcutaneous carboxyhemoglobin will be recorded. This study is cross-sectional and will only require one visit coinciding with the clinical visit. Analysis will determine the pairwise differences in SpCO between conditions tested.


Criteria

Inclusion Criteria: - diagnosis of asthma, pneumonia, allergic rhinitis, or none of the previous (control group) - Ability to complete study procedures Exclusion Criteria: - Cardiopulmonary disease outside of the specific conditions for inclusion - Prematurity - Congenital heart disease - Current diagnosis of more than one of the following: asthma, pneumonia, allergic rhinitis, cystic fibrosis, or - for controls - any current infection - Recent serious bacterial infection (except for pneumonia in the pneumonia group) - Concurrent clinical chest X-ray with findings other those that expected for the group (i.e. normal chest X-ray in pneumonia group or suspected pneumonia on chest X-ray in asthma group). To be determined by attending radiologist's interpretation.

  • Start Date

    2015-10-31

  • Last Updated

    2018-03-23

  • Sponsor

    Boston Children’s Hospital

  • Condition Name

    Pneumonia

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.